Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903118 | 0.88 | BCHE (0.43) | BCHEACHEGRM5 | |
| SCHEMBL9903615 | 0.87 | EGLN1 (0.39) | BCHEACHEALDH1A1GRM5CHRNB2 | |
| SCHEMBL9902619 | 0.81 | GRM5 (0.51) | ALDH1A1GRM5 | |
| SCHEMBL9902966 | 0.81 | BRAF (0.39) | BCHEACHEALDH1A1GRM5 | |
| SCHEMBL9903671 | 0.81 | GRM5 (0.38) | BCHEACHEALDH1A1GRM5 | |
| SCHEMBL9902914 | 0.80 | CHRNB2 (0.41) | ALDH1A1GRM5CHRNB2CHRNA4 | |
| SCHEMBL9902735 | 0.80 | PIK3CA (0.42) | ALDH1A1GRM5 | |
| SCHEMBL9902843 | 0.79 | AAK1 (0.50) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL6157594 | 0.78 | ALDH1A1 (0.38) | ALDH1A1GRM5 | |
| SCHEMBL9903498 | 0.78 | GRM5 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | NTRK3 784/4885BCHE 1499/4885ACHE 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.